XBiotech (XBIT)
Develops human-derived monoclonal antibodies through integrated Austin research, clinical development and manufacturing.
$2.20
At close−0.02 (−0.90%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions38 holders · as of Mar 31, 2026 | 6.54% | 1.99M shares | |
| Insiders6 holders · as of Jan 23, 2026 | 46.28% | 14.11M shares | |
| Otherremainder | 47.18% | 14.39M shares |
30.49M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
38 holders · 1.99M shares · 9 new positions · 16 increased · 11 reduced · 11 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 293.1K | 0.96% | +4.5K | May 13, 2026 |
| Geode Capital Management, LLC | 231.0K | 0.76% | +9.9K | May 15, 2026 |
| Vanguard Capital Management LLC | 201.0K | 0.66% | +201.0Knew | May 15, 2026 |
| RBF Capital, LLC | 198.5K | 0.65% | 0 | May 18, 2026 |
| Morgan Stanley | 165.6K | 0.54% | +2.1K | May 15, 2026 |
| Millennium Management LLC | 105.5K | 0.35% | −29.9K | May 15, 2026 |
| Bridgeway Capital Management, LLC | 98.4K | 0.32% | +8.9K | May 15, 2026 |
| Vanguard Fiduciary Trust Co | 91.6K | 0.30% | +91.6Knew | May 8, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| John Simard | 17.70% | 5.72M | 13G | Jan 23, 2026 ↗ |
| W. Thorpe McKenzie | 9.76% | 3.01M | 13G | Jan 23, 2026 ↗ |
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.
